Grifols | GRFS - Current Assets


Grifols reported EUR6.28B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 2.68M 1.05M Sep/2025
Arca Biopharma USD 355.16M 23.15M Sep/2025
aTyr Pharma USD 93.01M 5.52M Sep/2025
Bio Path USD 680K 1.44M Jun/2025
Brainstorm Cell Therapeutics USD 508K 1.01M Sep/2025
Capricor Therapeutics USD 100.95M 23.18M Sep/2025
Cara Therapeutics USD 43.13M 4.18M Jun/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Grifols EUR 6.28B 92.48M Sep/2025
Immunic USD 39.27M 20.57M Sep/2025
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024